Alzheimer's Disease Therapeutic

阿尔茨海默病治疗

基本信息

  • 批准号:
    8323257
  • 负责人:
  • 金额:
    $ 118.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-30 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Alzheimer's Disease (AD) is a significant neurological disorder that afflicts more than 4.5 million Americans and more than 10 million people worldwide. The lack of a cure for AD will result in a demand for better and safer AD drugs. All of the drugs on the market today have serious side effects. Recently, researchers at The Blanchette Rockefeller Neurosciences Institute, Rockville, MD have hypothesized and shown that protein kinase C (PKC) and its activation are important means of ameliorating AD pathophysiology and cognitive impairment. They have shown that sub-nanomolar concentrations of bryostatin 1, a potent PKC activator, dramatically enhance the generation of non-amyloidogenic soluble amyloid precursor protein (sAPP) in fibroblasts from AD patients. Bryostatin 1 was effective in reducing brain amyloid plaques (A240 and A242 in AD) in double-transgenic mice while improving behavioral outcomes and the rate of premature death. These researchers have also shown that bryostatin 1 not only produces a neuroprotective effect but also enhances cognitive memory in AD animal models. Bryostatin 1 is a complex cyclic macrolide molecule that occurs in very small concentrations (~ 5 to 25 ppm) in a bryozoan, sometimes referred to as a "sea moss" found off the coast in Southern California. Bryostatin 1 is also more hydrophobic than paclitaxel, the potent anticancer drug with well-known formulation difficulties. Aphios has developed and patented improved methodologies and manufacturing processes for cost-effectively isolating pharmaceutical-grade bryostatin 1 from Bugula neritina. Our scientists and engineers have also developed methods for formulating hydrophobic molecules such as bryostatin 1 in stable, readily bioavailable oil-based formulations, and novel nanotechnology formulations of bryostatin 1 that will further improve oral bioavailability. Aphios' Zindol(R) product, which contains oil soluble gingerols and shogaols, recently completed a successful Phase II/III clinical trial for nausea and emesis in cancer patients undergoing chemotherapy. Our Phase I Specific Aims are to: (1) Develop conventional and nanotechnology oral formulations of bryostatin 1; and (2) Test stability of selected formulations under accelerated conditions of temperature and humidity, and evaluate in vitro characteristics and in vivo efficacy. We have set three milestones to be achieved before moving on to Phase II. Our Phase I milestones are as follows: stable lyophilized and/or oil-based nanoparticles formulation of bryostatin-1 in the size range of 100 to 200 nm range containing 1 to 10 5g/mL bryostatin 1 with a drug:polymer ratios of 1:10 to 1:100; brief (5-15 minutes), low dosages (0.04-0.2 nM) and application frequencies 1-2 x /week will provide maximal PKC activation and minimal downregulation; and 30% to 50% enhancement of learning and memory in the wild type of mice and even greater enhancement in the transgenic mice due to neuroprotection. Our Phase II Specific Aims are as follows: (1) Specific Aim 1: For selected formulations, radioactive bryostatin 1 will be assayed to determine the pharmacokinetics and tissue distribution. Pharmacologic efficacy will also be measured, particularly in the brain and plasma compartments by total PKC activity, membrane/cytosolic PKC activity ratios, and phosphorylation of ERK 1/2 MAP Kinase; and (2) Specific Aim 2: Establish cGMP manufacturing of the bryostatin 1 API (active pharmaceutical ingredient) and FDP (final or formulated drug product) at the pilot-scale level. Establish a Drug Master File, design IND-enabling preclinical studies and Phase I/II clinical trials, and draft IND package: In a Phase III commercialization effort, we will conduct IND-enabling preclinical in vivo studies, including toxicology, efficacy, pharmacology and stability testing of selected formulation of bryostatin 1 drug product under Good Laboratory Practices (GLP) conditions. These studies will be conducted by a CRO such as Southern Research Institute or Covance Laboratories. As part of our commercialization effort, Aphios Corporation will also establish a wholly owned subsidiary Amylon Pharmaceuticals to focus on the discovery and development of novel therapeutics for Alzheimer's Disease and Cognitive Disorders with bryostatin-1 as its lead compound. Amylon Pharmaceuticals will raise a Series A round of $20 million USD in equity capital to accelerate the development of bryostatin 1 for Alzheimer's Disease and Cognitive Disorders. This capital will be utilized to: (i) establish a management and product development team; (ii) conduct Phase I human clinical trials; (iii) research and development of second- generation products; and (iv) manufacture cGMP products over a two-year period. Within 12 months of the Series A raise, Amylon plans to initiate the establishment of a $25 million USD Series B round to conduct Phase II clinical trials in year 3. Later, Amylon plans to do an IPO to raise $100 million to conduct Phase III clinical trials and commercialize bryostatin 1 for Alzheimer's Disease and Cognitive Disorders. Alternatively, at this stage, Amylon will merge with a mid-tier public company or be acquired by a multinational pharmaceutical company.
描述(申请人提供):阿尔茨海默病(AD)是一种严重的神经系统疾病,困扰着超过450万美国人和全球超过1000万人。缺乏治疗阿尔茨海默病的方法将导致对更好、更安全的阿尔茨海默病药物的需求。今天市场上所有的药物都有严重的副作用。最近,位于马里兰州罗克维尔的布兰切特·洛克菲勒神经科学研究所的研究人员提出假设,并证明蛋白激酶C(PKC)及其激活是改善AD病理生理和认知损害的重要手段。他们已经证明,亚纳摩尔浓度的Bryostatin 1,一种有效的PKC激活剂,显著增加了AD患者成纤维细胞中非淀粉样变性可溶性淀粉样前体蛋白(SAPP)的生成。Bryostatin 1有效地减少了双转基因小鼠的脑淀粉样斑块(AD中的A240和A242),同时改善了行为结果和过早死亡率。这些研究人员还表明,bryostatin 1不仅能产生神经保护作用,还能增强AD动物模型的认知记忆。Bryostatin 1是一种复杂的环状大环内酯分子,在苔藓虫中以非常小的浓度(~5至25ppm)出现,有时被称为在南加州海岸发现的“海苔”。Bryostatin 1的疏水性也比紫杉醇更强,紫杉醇是一种强效抗癌药物,存在众所周知的配方困难。Aphios已经开发并申请了改进的方法和制造工艺的专利,以经济高效地从Bugula neritina中分离出药用级Bryostatin 1。我们的科学家和工程师还开发了在稳定、易于生物利用的油基配方中配制Bryostatin 1等疏水分子的方法,以及将进一步提高口服生物利用度的新型纳米技术Bryostatin 1配方。Aphios公司的Zindol(R)产品含有油溶姜辣素和shogaol,最近成功地完成了治疗接受化疗的癌症患者恶心和呕吐的第二/第三阶段临床试验。我们第一阶段的具体目标是:(1)开发Bryostatin 1的传统和纳米技术口服制剂;(2)测试选定制剂在加速温度和湿度条件下的稳定性,并评估体外特性和体内疗效。在进入第二阶段之前,我们设定了三个里程碑。我们的第一阶段里程碑如下:稳定的冻干和/或油基纳米颗粒bryostatin-1的尺寸范围为100至200 nm,包含1至10 5g/mLbryostatin 1,药物:聚合物比例为1:10至1:100;简短(5-15分钟)、低剂量(0.04-0.2 nm)和应用频率1-2倍/周将提供最大的PKC激活和最小的下调;野生型小鼠的学习记忆能力提高30%至50%,由于神经保护,转基因小鼠的学习记忆能力提高更多。我们的第二阶段具体目标如下:(1)具体目标1:对于选定的制剂,将进行放射性Bryostatin 1的检测,以确定其药代动力学和组织分布。还将通过PKC总活性、膜/胞液PKC活性比率和ERK 1/2 MAP Kinase的磷酸化来衡量药理效果,特别是在大脑和血浆中;以及(2)具体目标2:在中试水平上建立Bryostatin 1 API(活性药物成分)和FDP(最终或配方药物产品)的cGMP制造。建立药物总档案,设计支持IND的临床前研究和I/II期临床试验,并起草IND包:在第三阶段商业化工作中,我们将在良好实验室规范(GLP)条件下进行支持IND的临床前体内研究,包括毒理学、有效性、药理学和选定配方的Bryostatin 1药物产品的稳定性测试。这些研究将由南方研究所或Covance实验室等CRO进行。作为我们商业化努力的一部分,Aphios Corporation还将成立一家全资子公司Amron PharmPharmticals,专注于发现和开发以Bryostatin-1为先导化合物的治疗阿尔茨海默病和认知障碍的新疗法。阿米伦制药公司将筹集2000万美元的首轮股权资本,以加快治疗阿尔茨海默氏症和认知障碍的Bryostatin 1的开发。这笔资金将用于:(I)建立管理和产品开发团队;(Ii)进行第一阶段人体临床试验;(Iii)第二代产品的研究和开发;以及(Iv)在两年内制造cGMP产品。在首轮融资的12个月内,Amylon计划启动2500万美元的B轮融资,在第三年进行第二阶段临床试验。稍后,Amylon计划进行首次公开募股(IPO),筹集1亿美元,用于进行第三阶段临床试验,并将治疗阿尔茨海默病和认知障碍的Bryostatin 1商业化。或者,在这个阶段,Amylon将与一家中端上市公司合并,或者被一家跨国制药公司收购。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Bryostatin-1 vs. TPPB: dose-dependent APP processing and PKC-α, -δ, and -ε isoform activation in SH-SY5Y neuronal cells.
Acute oral Bryostatin-1 administration improves learning deficits in the APP/PS1 transgenic mouse model of Alzheimer's disease.
  • DOI:
    10.2174/1567205012666141218141904
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    2.1
  • 作者:
    L. Schrott;K. Jackson;P. Yi;F. Dietz;G. S. Johnson;T. Basting;G. Purdum;T. Tyler;J. Ríos;T. Castor;J. Alexander
  • 通讯作者:
    L. Schrott;K. Jackson;P. Yi;F. Dietz;G. S. Johnson;T. Basting;G. Purdum;T. Tyler;J. Ríos;T. Castor;J. Alexander
Nanoparticle-Encapsulated Bryostatin-1 Activates α-Secretase and PKC Isoforms In vitro and Facilitates Acquisition and Retention of Spatial Learning in an Alzheimer's Disease Mouse Model.
纳米颗粒封装的 Bryostatin-1 在体外激活 α-分泌酶和 PKC 同工型,并促进阿尔茨海默病小鼠模型空间学习的获取和保留。
  • DOI:
    10.2174/1567205018666210218155835
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    2.1
  • 作者:
    Schrott,Lisa;Yi,Ping;Jackson,Kasey;Jackson,GabrielS;Webb,Christopher;Minagar,Alireza;Yun,JWinny;Purdum,Geoffrey;Rios,DavidJ;Tyler,TheodoreA;Vizcanio,MariaI;Castor,JudithL;Castor,Trevor;Alexander,JonathanS
  • 通讯作者:
    Alexander,JonathanS
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TREVOR P. CASTOR其他文献

TREVOR P. CASTOR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TREVOR P. CASTOR', 18)}}的其他基金

Double-Encapsulated mRNA Vaccine for COVID-19
适用于 COVID-19 的双囊 mRNA 疫苗
  • 批准号:
    10611763
  • 财政年份:
    2023
  • 资助金额:
    $ 118.35万
  • 项目类别:
Combination Therapeutic for Chronic Opioid Use Disorder Relapse
慢性阿片类药物使用障碍复发的联合治疗
  • 批准号:
    10706844
  • 财政年份:
    2023
  • 资助金额:
    $ 118.35万
  • 项目类别:
Development of cGMP Manufacturing Process for CBD
CBD cGMP 生产工艺的开发
  • 批准号:
    8966448
  • 财政年份:
    2015
  • 资助金额:
    $ 118.35万
  • 项目类别:
Development of SFS Fractionators
SFS分馏塔的开发
  • 批准号:
    8712743
  • 财政年份:
    2014
  • 资助金额:
    $ 118.35万
  • 项目类别:
Development of cGMP Manufacturing Process for CBD
CBD cGMP 生产工艺的开发
  • 批准号:
    8834719
  • 财政年份:
    2014
  • 资助金额:
    $ 118.35万
  • 项目类别:
Alzheimer's Disease Therapeutic
阿尔茨海默病治疗
  • 批准号:
    8306435
  • 财政年份:
    2010
  • 资助金额:
    $ 118.35万
  • 项目类别:
Alzheimer's Disease Therapeutic
阿尔茨海默病治疗
  • 批准号:
    7917968
  • 财政年份:
    2010
  • 资助金额:
    $ 118.35万
  • 项目类别:
CFI Pathogen Inactivation Technology
CFI病原体灭活技术
  • 批准号:
    7830669
  • 财政年份:
    2009
  • 资助金额:
    $ 118.35万
  • 项目类别:
CFI Inactivation of Human Plasma
人血浆的 CFI 灭活
  • 批准号:
    7675084
  • 财政年份:
    2009
  • 资助金额:
    $ 118.35万
  • 项目类别:
CFI Pathogen Inactivation Technology
CFI病原体灭活技术
  • 批准号:
    7933943
  • 财政年份:
    2009
  • 资助金额:
    $ 118.35万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了